9 completed, 6 recruiting, 3 withdrawn, 2 not yet recruiting. 22 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 9, Recruiting 6, Withdrawn 3, Not yet recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 3 | 5 | Not yet recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow testosterone cypionate: new trials by email Literature Review of testosterone cypionate trials Research Report on testosterone cypionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| The Anabolic Effect of Testosterone on Pelvic Floor Muscles Testosterone cypionate, Placebo - Stress Urinary Incontinence, Menopause | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 30 | 2025-02-15 | 2026-06-26 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) Testosterone Cypionate, Placebo - Pain, Opioid Use | Phase 2 | Completed | Brigham and Women's Hospital | 36 | 2022-11-15 | 2026-04-15 |
| Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair Testosterone cypionate, Placebos - Rotator Cuff Tears | Phase 2 / Phase 3 | Withdrawn | Orthopedic Institute, Sioux Falls, SD | 2021-08-01 | 2022-03-15 | |
| Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) Testosterone Cypionate, Darolutamide - Prostate Cancer | Phase 2 | Completed | Latin American Cooperative Oncology Group | 51 | 2021-06-09 | 2026-08-28 |
| Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy Testosterone cypionate - Prostate Cancer | Phase 2 | Completed | Hospital Sirio-Libanes | 20 | 2020-09-22 | 2022-08-03 |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Testosterone cypionate, Enzalutamide, Testosterone enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 150 | 2020-08-19 | 2026-07-17 |
| COMbination of Bipolar Androgen Therapy and Nivolumab Testosterone cypionate, Nivolumab - Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 45 | 2018-09-05 | 2024-02-20 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
| Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness Testosterone cypionate, Standard nutrition and physical therapy at ICU - Critical Illness Polyneuropathies | Phase 2 / Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 30 | 2016-10-01 | 2017-02-01 |
| Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction Testosterone, Normal Saline - Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase | Phase 2 / Phase 3 | Withdrawn | Texas Tech University Health Sciences Center | 2016-08-01 | 2019-11-21 | |
| Subcutaneous Testosterone Project Subcutaneous testosterone - Gender Dysphoria | Phase 1 / Phase 2 | Completed | University of British Columbia | 14 | 2015-07-01 | 2016-06-06 |
| Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Testosterone cypionate, Enzalutamide, Testosterone Enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 222 | 2015-01-01 | 2020-11-06 |
| RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 112 | 2014-08-25 | 2022-06-27 |
Showing 20 of 22. Sign in to see all of them.
Prostatic Neoplasms (10) · Hypogonadism (3) · Anorexia Nervosa (1) · Back Pain (1) · Bone Diseases (1) · Bone Resorption (1) · Central Nervous System Diseases (1) · Endocrine System Diseases (1) · Gender Dysphoria (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Gonadal Disorders (1) · Male Urogenital Diseases (1) · Motor Activity (1) · Musculoskeletal Diseases (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Brigham and Women's Hospital (2) · University of Washington (2) · ECOG-ACRIN Cancer Research Group (1) · Hospital Sirio-Libanes (1) · Hospital de Clinicas de Porto Alegre (1) · Latin American Cooperative Oncology Group (1) · Massachusetts General Hospital (1) · Orthopedic Institute, Sioux Falls, SD (1) · Texas Tech University Health Sciences Center (1) · University of British Columbia (1) · VA Office of Research and Development (1) · Yale University (1)
United States (17) · Brazil (3) · Canada (1)
Samuel Denmeade, MD (6) · Michael Schweizer (2) · Craig W Spellman, DO (1) · Diogo Assed Bastos (1) · Grace Huang, MD (1) · Joseph W Kim, MD (1) · Joshua F Yarrow, PhD MS BS (1) · Keith M Baumgarten, MD (1) · Laura Sena, MD, PhD (1) · Madhusmita Misra, MD (1) · Mark Markowski, MD, Ph.D (1) · Mary Ensom, Pharm D/PhD (1) · Michael T. Schweizer (1) · Osama Mukarram, MD (1) · Pedro Henrique Isaacson Velho (1)
PMID 29248236, PMID 32624280, PMID 33383350, PMID 33617303, PMID 35027313, PMID 35938545, PMID 38167882
P30CA015704 (1), P50CA097186 (1), P50CA272391 (1), R01CA184012 (1), R01DK136904 (1), U10CA180820 (1)